Background Breast cancer is the global leading cancer burden in women and the hormone
receptor-positive (HR+) subtype is a major part of breast cancer. Though cyclin-dependent …

Simple Summary Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are widely used to
treat metastatic hormone receptor-positive/human epidermal growth factor receptor 2 …

Acquired resistance to cyclin-dependent kinases 4 and 6 (CDK4/6) inhibition in estrogen
receptor-positive (ER+) breast cancer remains a significant clinical challenge. Efforts to …

The CDK4/6 inhibitor palbociclib is currently being used in combination with endocrine
therapy to treat advanced ER positive breast cancer patients. While this treatment has …

Recently, cyclin-dependent kinase (CDK) 4/6 inhibitors have been widely used to treat
advanced hormone receptor-positive breast cancer. Despite promising clinical outcomes …

Background The cyclin D1-cyclin dependent kinases (CDK) 4/6 inhibitor palbociclib in
combination with endocrine therapy shows remarkable efficacy in the management of …

CDK4/6 inhibitors are the standard treatment in advanced HR+/HER2− breast cancer
patients. Nevertheless, the resistance to CDK4/6 inhibitors is inevitable and the strategies to …

Purpose The management of triple-negative breast cancer (TNBC) remains a significant
clinical challenge due to the lack of effective targeted therapies. Inhibitors of the cyclin …

Background CDK4/6 inhibitors combined with endocrine therapy has become the preferred
treatment approach for patients with estrogen receptor-positive metastatic breast cancer …

CDK4/6 inhibitors represent a new treatment standard for hormone receptor-positive (HR+),
HER2-negative advanced breast cancer (BC) patients. Although efficacious, resistance to …